Boulder, CO, United States of America

Mark Christopher Lohman


Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Boulder, CO (US) (2003 - 2004)
  • Superior, CO (US) (2006)

Company Filing History:


Years Active: 2003-2006

Loading Chart...
3 patents (USPTO):

Title: Mark Christopher Lohman: Innovator in Pharmaceutical Research

Introduction

Mark Christopher Lohman is a notable inventor based in Boulder, CO (US). He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target resistant neoplasms. With a total of 3 patents to his name, Lohman continues to push the boundaries of innovation in medicine.

Latest Patents

Lohman's latest patents include "Compounds and methods for inhibiting MRP1," which relates to a compound of formula (I) that is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1. Another significant patent is "Methods and compounds for inhibiting MRP1," which describes a method of inhibiting MRP1 in a mammal by administering an effective amount of a compound of formula (I).

Career Highlights

Lohman is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work focuses on developing innovative solutions to combat drug resistance in cancer treatment. His research has the potential to improve patient outcomes and advance the field of oncology.

Collaborations

Throughout his career, Lohman has collaborated with esteemed colleagues such as Peter Ambrose Lander and Rosanne Bonjouklian. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Mark Christopher Lohman exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborative efforts are paving the way for advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…